Opus Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRD research report →
Range $8 – $10
Price Chart
About the company
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
- CEO
- George Magrath
- IPO
- 2015
- Employees
- 28
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on IRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $340.17M
- P/E
- -3.24
- Fwd P/E
- 34.23
- PEG
- 0.08
- P/S
- 34.51
- P/B
- -30.29
- EV/EBITDA
- -2.73
- Div Yield
- 0.00%
- Gross Margin
- 99.87%
- Op Margin
- -513.47%
- Net Margin
- -1091.82%
- ROE
- 1147.63%
- ROIC
- -59.29%
Latest fiscal year · YoY change
- Revenue
- $14.20M+29.1%
- Gross Profit
- $14.20M+29.1%
- Op Income
- $-38,599,000
- Net Income
- $-49,591,000+13.8%
- EPS
- $-0.80+62.8%
- OCF Growth
- -37.8%
- FCF Growth
- -37.8%
- 52W High
- $5.81
- 52W Low
- $1.12
- 50D MA
- $3.74
- 200D MA
- $3.57
- Beta
- 0.58
- RSI (14)
- 63
- Avg Volume
- 941.85K
No earnings-call transcripts are available for IRD yet.
- Free Float
- 42.4%
- Shares Outstanding
- 82.57M
- Float Shares
- 34.98M
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 64 ETFs
Biggest fund positions in IRD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 23, 26 | YERXA BENJAMIN R | sell | 7,429 |
| Jul 23, 26 | SCHACHLE JOSEPH K | sell | 4,644 |
| Jul 23, 26 | Magrath George | sell | 9,475 |
| Jul 23, 26 | Gagnon Robert E. | sell | 7,783 |
| May 18, 26 | Foundation Fighting Blindness Retinal Degeneration Fund | sell | 1,700,000 |
| Apr 23, 26 | YERXA BENJAMIN R | sell | 7,470 |
| Apr 23, 26 | SCHACHLE JOSEPH K | sell | 4,697 |
| Apr 23, 26 | Zaremba Rabourn Amy | sell | 1,641 |
| Apr 23, 26 | Magrath George | sell | 9,511 |
| Apr 23, 26 | Jayagopal Ashwath | sell | 7,542 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRD coverage
Recent articles, reports, and earnings notes.
No research on IRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRD report →Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Aug 19
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 6
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
globenewswire.com · Aug 3
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
globenewswire.com · Jul 9
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
globenewswire.com · Jul 6
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
globenewswire.com · Jun 26
Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript
seekingalpha.com · Jun 17
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
globenewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.